Welcome to our dedicated page for Enveric Biosciences news (Ticker: ENVB), a resource for investors and traders seeking the latest updates and insights on Enveric Biosciences stock.
Enveric Biosciences develops neuroplastogenic small-molecule therapeutics for psychiatric and neurological disorders. Its news commonly centers on EB-003, a lead candidate from the EVM301 Series designed to promote neuroplasticity without hallucinogenic effects and to modulate 5-HT2A and 5-HT1B receptors. Company updates also discuss preclinical models tied to PTSD, depression, anxiety and related neuropsychiatric conditions.
Recurring announcements include intellectual-property activity for the EVM301 and EVM401 Series, trademark registrations, corporate and financial results, and capital actions involving common stock, pre-funded warrants and other warrants. Enveric also reports business-development and conference activity around non-hallucinogenic and psychedelic-inspired therapeutic approaches.
Enveric Biosciences (NASDAQ: ENVB) has announced a strategic development collaboration and exclusive supply agreement with PureForm Global, Inc. This partnership aims to develop cannabinoid medicines that alleviate treatment side effects for cancer patients. PureForm will be Enveric's exclusive supplier of synthetic, non-cannabis-based CBD, with plans targeting conditions like radiodermatitis and chemotherapy-induced neuropathy. The agreement ensures a consistent supply of high-quality CBD for clinical studies and emphasizes rigorous scientific research to enhance treatment options for patients.
Enveric Biosciences, Inc. (NASDAQ: ENVB) announced the completion of its registered direct offering on February 11, 2021, selling 3,007,026 shares at $4.27 each, raising approximately $12.84 million. After fees, the net proceeds are about $11.5 million, which will be used for working capital and corporate purposes. Investors received warrants for an additional 1,503,513 shares at $4.90 each. The offering was made under existing SEC registration statements.
Enveric Biosciences Inc. (NASDAQ: ENVB) announced a registered direct offering of 3,007,026 shares at $4.27 each, totaling approximately $12.84 million in gross proceeds. The company will also issue unregistered warrants to acquire an additional 1,503,513 shares at $4.90 each. The offering, expected to close on February 11, 2021, aims to fund working capital and general corporate purposes. After the offering, Enveric will have 18,336,367 shares outstanding.
Enveric Biosciences (NASDAQ: ENVB) issued a shareholder letter highlighting corporate initiatives and strategic vision to enhance quality of life for cancer patients. The company recently secured $10 million in financing and aims to accelerate its pipeline focusing on supportive care therapies addressing severe side effects of cancer treatments. Enveric's leadership team comprises seasoned executives from top healthcare firms. The company plans to collaborate with leading oncology centers to advance its research in cancer treatment side effects like radiation dermatitis and CIPN, targeting clinical trials in 2021.
Enveric Biosciences (NASDAQ: ENVB) has closed a $10 million registered direct offering on January 14, 2021, selling 2,221,358 shares at a price of $4.5018 per share. The offering included unregistered warrants for 1,666,019 shares at $4.9519 per share, exercisable immediately for five years. After costs, net proceeds are approximately $9 million, which will be allocated for working capital and general corporate purposes. The offering was made under a Form S-3 registration statement previously filed with the SEC.
Enveric Biosciences Inc. (NASDAQ: ENVB) has announced a registered direct offering of 2,221,358 shares at $4.5018 per share, totaling approximately $10 million in gross proceeds. The company will also issue warrants for 1,666,019 shares at $4.9519 each. The offering is set to close on January 14, 2021, pending customary conditions. The funds will be used for general corporate purposes, potentially enhancing growth. Palladium Capital Group served as the financial advisor for this transaction.
Enveric Biosciences (NASDAQ: ENVB) has appointed Dr. Marcus Schabacker to its Board of Directors on January 5, 2021. Dr. Schabacker, possessing over 35 years of healthcare experience, is recognized for his work at ECRI Institute and Baxter Healthcare. His expertise aligns with Enveric's mission to develop cannabinoid medicines aimed at improving the quality of life for cancer patients, particularly focusing on treating side effects from cancer therapies. The company aims to leverage Dr. Schabacker's insights to enhance its research and development efforts.